Claudia Ibarra Sells 7,605 Shares of DermTech (NASDAQ:DMTK) Stock

DermTech (NASDAQ:DMTK) COO Claudia Ibarra sold 7,605 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $10.82, for a total transaction of $82,286.10. Following the completion of the sale, the chief operating officer now directly owns 120,470 shares of the company’s stock, valued at $1,303,485.40. The transaction was disclosed in a filing with the SEC, which is available at this link.

NASDAQ:DMTK opened at $11.39 on Wednesday. The stock’s fifty day moving average is $11.59 and its 200 day moving average is $12.38. DermTech has a fifty-two week low of $5.06 and a fifty-two week high of $16.95. The firm has a market capitalization of $222.12 million, a PE ratio of -5.72 and a beta of 0.77.

DermTech (NASDAQ:DMTK) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.21). The business had revenue of $0.84 million during the quarter. DermTech had a negative return on equity of 69.48% and a negative net margin of 599.76%.

Several equities research analysts recently issued reports on DMTK shares. ValuEngine lowered shares of DermTech from a “buy” rating to a “hold” rating in a report on Wednesday, August 26th. Brookline Capital Management initiated coverage on DermTech in a research note on Friday, September 11th. They issued a “buy” rating for the company. Finally, Cowen started coverage on DermTech in a research note on Thursday, September 10th. They issued an “outperform” rating and a $20.00 price target for the company.

Several institutional investors have recently made changes to their positions in DMTK. RTW Investments LP lifted its holdings in shares of DermTech by 9.8% during the second quarter. RTW Investments LP now owns 2,855,765 shares of the company’s stock worth $37,782,000 after purchasing an additional 255,036 shares during the period. Federated Hermes Inc. boosted its stake in shares of DermTech by 1,587.2% in the second quarter. Federated Hermes Inc. now owns 1,214,862 shares of the company’s stock worth $16,073,000 after acquiring an additional 1,142,858 shares during the last quarter. Casdin Capital LLC acquired a new position in DermTech during the first quarter worth $5,642,000. Perceptive Advisors LLC boosted its stake in DermTech by 70.4% during the second quarter. Perceptive Advisors LLC now owns 487,121 shares of the company’s stock worth $6,445,000 after buying an additional 201,265 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in DermTech by 25.3% during the first quarter. Victory Capital Management Inc. now owns 385,397 shares of the company’s stock worth $4,336,000 after buying an additional 77,704 shares during the last quarter. Hedge funds and other institutional investors own 50.06% of the company’s stock.

About DermTech

DermTech, Inc, a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Recommended Story: What does it mean to hold a stock in street name?

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.